Table 2

Meta-analysis results of any grade immune-related adverse events of interest in the as-treated population

Immune-related adverse eventsImmuno vs chemoImmuno plus chemo vs chemoImmuno vs immuno plus chemo
ImmunoChemoRisk ratio (95% CI)Immuno plus chemoChemoRisk ratio (95% CI)ImmunoImmuno plus chemoRisk ratio (95% CI)
No. of events/ No. of patientsNo. of events/
No. of patients
No. of events/ No. of patientsNo. of events/ No. of patientsNo. of events/ No. of patientsNo. of events/ No. of patients
Hypothyroidism77/6369/6158.27 (4.19 to 16.35)185/184022/13846.29 (4.02 to 9.83)262/247631/19991.32 (0.58 to 2.97)
Pneumonitis53/6363/61517.08 (5.37 to 54.38)110/184025/13843.30 (2.15 to 5.06)163/247628/19995.18 (1.51 to 17.78)
Hyperthyroidism39/6364/6159.43 (3.39 to 26.23)82/184014/13844.29 (1.71 to 10.77)121/247618/19992.20 (0.56 to 8.70)
Severe skin reaction15/6362/6157.25 (1.67 to 31.58)18/10339/8181.41 (0.66 to 3.07)33/166911/14335.11 (0.97 to 26.82)
Thyroiditis10/6360/61520.31 (1.19 to 345.80)4/6830/4823.87 (0.50 to 30.14)14/13190/10975.25 (0.16 to 173.62)
Hepatitis9/6360/61518.37 (1.07 to 315.00)127/178150/13221.91 (1.40 to 2.59)136/241750/19379.62 (0.55 to 167.78)
Adrenal insufficiency4/6361/6153.87 (0.43 to 34.51)8/8781/4342.80 (0.49 to 15.87)12/15142/10491.38 (0.08 to 22.69)
Hypophysitis3/6360/6156.77 (0.35 to 130.78)6/6830/4825.02 (0.64 to 39.42)9/13190/10971.35 (0.04 to 49.74)
Nephritis3/6360/6156.77 (0.35 to 130.78)9/6832/4822.63 (0.58 to 11.92)12/13192/10972.57 (0.09 to 71.56)
Pancreatitis1/6360/6152.90 (0.12 to 71.08)9/11693/7081.85 (0.54 to 6.35)10/18053/13231.57 (0.05 to 48.00)
Infusion reaction10/63626/6150.37 (0.18 to 0.76)29/136713/11521.84 (0.95 to 3.54)39/200339/17670.20 (0.08 to 0.53)
Colitis7/6362/6153.38 (0.71 to 16.23)33/18405/13844.00 (1.76 to 9.14)40/24767/19990.85 (0.14 to 4.95)
  • Chemo, chemotherapy; ; Immuno, immunotherapy alone; Immuno plus chemo, immunotherapy plus chemotherapy.